Skip to main content
Fig. 1 | BMC Medical Genomics

Fig. 1

From: Exonic variants undergoing allele-specific selection in cancers

Fig. 1

Illustration of the study scheme. a Overview of the analysis. Whole-exome sequencing from patients is used to identify heterozygotes and assess AI. To generate the null distribution of the selection parameter π, the identity of the promoted allele (A or B) is swapped repeatedly, with 50% probability each time, and the resulting π recomputed each time. Venn diagrams showing the numbers of AI alleles identified in four cancer types at the significance level of b 0.05; c 0.01 and d 0.001

Back to article page